Recent studies have suggested oxytocin as a possible drug to treat social deficits caused by autism spectrum disorder (ASD), but the safety of intranasal oxytocin in autistic patients has not been established. The aim of this review was to characterize the side-effect profile of long-term intranasal oxytocin in treatment of ASD compared to placebo. All randomized controlled trials of intranasal oxytocin in the treatment of ASD published before 1 January 2017 that reported safety data were identified from databases, including PubMed, Embase, Cochrane Library, and International Pharmaceutical Abstract. Relevant data from the selected studies were then extracted for meta-analysis to estimate the pooled risk ratio for the most common adverse events. Descriptive analysis of severe adverse events was also conducted. Of the 223 participants in the five included studies, 123 were given oxytocin and 100 were given placebos. Nasal discomfort (14.3%), tiredness (7.2%), irritability (9.0%), diarrhea (4.5%), and skin irritation (4.5%) were the most common adverse events. None of these common adverse events was statistically associated with treatment allocation according to meta-analysis using pooled data (all P-values > 0.1). Five severe adverse events were reported, namely aggression (one in placebo, two in oxytocin) and seizures (one in placebo, one in oxytocin). Results from this systematic review support intranasal oxytocin as well tolerated and safe for use in the ASD population. Larger clinical trials should be conducted to establish the efficacy of intranasal oxytocin as a treatment of ASD.
A UTISM SPECTRUM DISORDER (ASD) is a neurodevelopmental disorder that affects the social functioning of an individual. The core symptoms of ASD include repetitive behavior and inability to interact and communicate well, relative to healthy individuals in their age group. Difficulty in socializing among patients with ASD stems from their inability to interpret and reciprocate social cues, such as facial expression and body language. Their repetitive behavior includes adherence to a routine or obsessions with certain objects and/or activities. 1 In some patients, language impairment is also apparent. The severity of patients' symptoms can vary widely depending on where they lie on the spectrum. Under the DSM-5, previously separate disorders with very similar symptoms, namely autistic disorder, Asperger's disorder, and pervasive developmental disorder not otherwise specified, were consolidated under the blanket term ASD. 1 However, some clinical trials continue to differentiate and report according to the different sub-divisions of ASD. In this systematic review, the definition of ASD used follows that of DSM-5 and DSM-IV. There is currently no cure for ASD, which is estimated to affect about 1% of the population. 1 Recent studies have suggested that intranasal oxytocin could be a possible treatment for ASD. [2] [3] [4] [5] Oxytocin is a human peptide hormone produced in the hypothalamus and released into the blood through the pituitary gland. Oxytocin is associated with various physiological and neurological processes, but in the context of ASD, oxytocin's ability to mediate the formation of bonds between individuals is the most relevant. 6 Given oxytocin's role in influencing social behavior, it is possible that ASD is linked to an individual's inability to produce oxytocin or insensitivity to oxytocin. Hence, direct administration of oxytocin could yield improvements in social functioning in ASD patients.
Elevated oxytocin has also been shown to be detectable in cerebrospinal fluid and blood in humans after an intranasal administration of 24 IU, 7 indicating that intranasal oxytocin has sufficient bioavailability. However, clinical trials to assess the efficacy of intranasal oxytocin conducted to date have been limited in both scale (i.e., number of participants) and experimental design. 8 Before considering larger-scale trials and clinical applications of intranasal oxytocin in ASD patients, it is important for us to establish the safety of intranasal oxytocin in the ASD population.
Oxytocin is commonly used in the induction of childbirth or in abortions by initiating uterine contractions. As such, the adverse effects of oxytocin are rather well known, which may include anaphylactic reaction, arrhythmia, nausea, and vomiting. 9 However, this drug is usually administered by the intravenous route rather than by the intranasal route. In addition, it is not known if the effect of oxytocin in healthy populations is the same as the effect in the autistic population. Therefore, there is a need to determine the safety of administering intranasal oxytocin in autistic patients.
Thus, the objective of this review was to characterize the side-effect profile of intranasal oxytocin in treatment of ASD compared to placebo. The secondary objective was to assess the occurrence of severe adverse effects observed in clinical trials.
METHODS

Search strategies and inclusion criteria
This systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). 10 Randomized controlled trials published before 1 January 2017 that compared the intervention of oxytocin administration via the intranasal route against placebo were searched from PubMed, Embase, International Pharmaceutical Abstract, and Cochrane Library. Keywords used were: 'intranasal oxytocin,' 'oxytocin nasal spray,' 'oxytocin spray,' 'syntocinon spray,' 'Syntocinon nasal spray,' 'autism,' 'safety,' 'adverse,' and 'side effects.' Synonyms of the search terms were grouped together with Boolean commands where the databases support it. After removing duplicates, two reviewers (Q. Cai and K. Z. Yap) reviewed the titles and abstracts of the remaining search results to exclude those that did not involve oxytocin, human subjects with ASD diagnosed according to DSM-IV or DSM-5, or were not original studies. The remaining studies were then read in full to select only those that involved daily administration of intranasal oxytocin for a period of at least 1 month. Authors of studies that did not report adverse events fully were contacted for the missing adverse events data. Studies that used either parallel-group or crossover design were accepted. Any disagreements between the reviewers were mediated by a third reviewer (L. Feng).
Data extraction and meta-analysis
Data pertaining to the characteristic of the included trials were extracted. These included date of publication, length of study period, number of participants in oxytocin and placebo groups, participant demographics (age, sex), country of trial, method of assessing side-effects, dose of drug given, and brand/ formulation of oxytocin spray. The frequency and type of adverse events were extracted for the meta-analysis. Adverse events that were classified as severe by the original investigators of the trials were also noted.
Statistical heterogeneity between the selected studies was determined using χ 2 and I 2 statistics. The risk of bias in the studies was assessed using the Cochrane Collaboration's tool for assessing risk of bias. Meta-analysis was conducted using Review Manager 5.3 where the pooled risk ratios (RR) of the common adverse events (with at least 10 incidences) between oxytocin and placebo groups were estimated using the Mantel-Haenszel method under the fixed effect model. Sensitivity analysis was conducted using the random effects model. The 95% confidence intervals (CI) of the RR were also calculated.
RESULTS
Description of search strategy
In total, the search process yielded 80 unique studies. Based on the titles and abstracts, 68 studies were rejected. 2, 5, 8, Based on full text review of the remaining 12 studies, five were rejected for being short-term studies (less than a month), 3, 4, [77] [78] [79] while one was rejected for not being a randomized controlled trial. 80 The rejected studies are presented in Table S1 . Finally, six studies [81] [82] [83] [84] [85] [86] met the inclusion criteria and were included in this review. The search strategy is summarized in Fig. 1 .
Description of included studies
Of these six studies, three of them conducted by Yatawara et al., 82 Munesue et al., 86 and Watanabe et al. 81 employed the crossover study design. These trials consisted of two phases, whereby one group received oxytocin while the other received placebo in the first phase, then the two groups switched treatments in the second phase. The biological halflife of oxytocin had been found to be around 2 h. 87 Therefore, for these crossover trials, it was deemed that a washout period was unnecessary due to limited carryover effects. Hence, it was decided that data from both phases of the crossover trials would be used regardless of the length of the washout periods. A detailed description of the included studies can be found in Table 1 . [81] [82] [83] [84] [85] [86] These studies contributed to a total of 285 participants, with 131 of them receiving placebo and 154 of them receiving intranasal oxytocin for at least a month. All 261 male and 24 female participants had been diagnosed with ASD.
Participants in the crossover trials were counted twice -once in the placebo group and once in the oxytocin group -as they received both drugs.
All six of the selected studies reported on the occurrence of adverse events. Five studies listed all observed adverse events and provided the number of participants who suffered each adverse event separately. However, the study by Yatawara et al. 82 only stated the total number of adverse events without providing detailed breakdown for each type of adverse event separately. Hence, only the five aforementioned studies were included in the metaanalysis.
Only Yatawara et al. 82 and Munesue et al.
86
reported severe adverse events. In all, two of these occurred in the placebo group, and three in the oxytocin group. One participant experienced convulsions in both the placebo and oxytocin phases and hence contributed to the severe adverse events count for both oxytocin and placebo.
Heterogeneity among included studies
Inclusion and exclusion criteria of subjects used in the studies The details on the inclusion and exclusion criteria of subjects in each of the six studies can be found in Table S2 . The inclusion and exclusion criteria used in the six studies varied considerably in terms of age, sex, diagnosis, IQ, medical history, co-medication, substance dependence, and comorbidities. All studies except for Kosaka et al. 85 recruited participants diagnosed with ASD as defined by the DSM-IV-TR. Kosaka et al. 85 did not include participants diagnosed with Asperger's syndrome. Despite this, this difference was tolerable given the similarities between the disorders categorized under ASD.
Other differences in inclusion criteria of participants in the six trials include age and sex. Guastella et al. 83 and Yatawara et al. 82 focused specifically on children and adolescents, while the other studies recruited only adults. Ideally, subgroup analysis would be conducted to assess the differences in the adverse effects of oxytocin observed between children and adults. However, the sample size was deemed to be too small for the results to be meaningful. As for sex, three of the studies recruited both male and female participants, while the other three excluded females from the studies. Due to the low numbers of female participants (n = 24), subgroup analysis was not conducted, as it was unlikely to give meaningful results.
Dose and intervention used in the studies
The dose of oxytocin administered in each study varied from 16 to 48 IU per day. Four out of the six studies administered intranasal oxytocin with the brand name Syntocinon. 81, [84] [85] [86] Out of these four studies, two of them used a placebo that contained all the ingredients of Syntocinon except oxytocin, 81, 86 while Kosaka et al. 85 did not specify the formulation of the placebo used, and Anagnostou et al. 84 used normal saline as the placebo. For the two remaining studies that did not use Syntocinon, Guastella et al. 83 and Yatawara et al. 82 listed all the ingredients within the nasal sprays, with the placebo having the same ingredients as the oxytocin spray except for oxytocin.
Statistical heterogeneity χ 2 and I 2 statistics indicate that the statistical heterogeneity of the meta-analyses was low, with I 2 values less than 40% for all meta-analyses.
Risk of bias in included studies
A summary of the risk of bias in the included studies can be found in Table S3 . 
Selection bias
Guastella et al. 83 and Yatawara et al. 82 did not specify the method of randomization used in the allocation of the participants. In addition, Yatawara et al. 82 also did not mention the method of allocation concealment. The other four studies employed a method whereby the allocation sequence generation was centralized, such as through a statistician uninvolved in the trial. This allocation sequence was then concealed from all personnel involved in the studies, thereby removing selection bias from the trials.
Performance bias
All six of the studies satisfactorily demonstrated double blinding in the trials.
Detection bias
The reporting of adverse events was done either by the participants themselves or by their caregivers. Hence, blinding of the participants was equivalent to blinding of assessors. As all six studies had satisfactory blinding of the participants, risk of detection bias was deemed to be low for all six trials.
Attrition bias
For Yatawara et al., 82 eight out of 39 participants were excluded, and two of those eight were excluded due to adverse events. These events were not reported, hence leading to incomplete data. Therefore, this study was excluded from the metaanalysis.
Reporting bias
Reporting bias was detected in the study by Yatawara et al., 82 as the specific types of adverse events were not reported. Although attempts were made to contact the original authors for the missing data, no response was received.
Other biases: Bias due to methodology The method of collecting side-effect data could potentially introduce bias. Given that safety was not the primary outcome being measured in all of the included studies, it is possible that the methodology used for assessing adverse events would result in under-reporting of adverse events. Kosaka et al., 85 Anagnostou et al., 84 and Watanabe et al. 81 did not provide adequate information on how adverse Reported adverse events of oxytocin use in autistic patients
Common adverse events
The prevalence of all observed adverse events is summarized in Table S4 , while the number of adverse events in each included study is found in Table S5 . Common adverse events were nasal discomfort (n = 32, 14.3%), tiredness (n = 16, 7.2%), irritability (n = 19, 8.5%), diarrhea (n = 10, 4.5%), and skin irritation (n = 10, 4.5%). The prevalence of the identified common adverse events are presented in Table 2 . 81, [83] [84] [85] [86] The forest plots for pooled RR of these common adverse events are shown in Figure 2 . 81, [83] [84] [85] [86] No statistically significant association was found between intranasal oxytocin use and the side-effects.
The RR of skin irritation between the oxytocin and placebo group was 1.48 (95%CI, 0.45-4.85; Pvalue = 0.52). The RR of nasal discomfort between the oxytocin and placebo groups was found to be 0.92 (95%CI, 0.50-1.70; P-value = 0.79). The RR of irritability between the oxytocin and placebo group was 0.70. (95%CI, 0.33-1.50; P-value = 0.36). Tiredness had an RR of 0.85 (95%CI, 0.34-2.15; P-value = 0.73) between the oxytocin and placebo groups. The RR of diarrhea between the oxytocin and placebo groups was found to be 1.00 (95% CI, 0.33-3.01; P-value = 1.00).
Severe adverse events
Only Yatawara et al. 82 and Munesue et al. 86 reported occurrences of severe adverse events. Yatawara et al. 82 reported three instances of hyperactivity and aggression among different participants, two of which occurred in week 1 of the oxytocin phase and one in week 1 of the placebo phase of the crossover trial. The study stated that these adverse reactions ceased once treatment was discontinued.
Munesue et al. 86 reported seizures in two participants. For the first participant, the seizure occurred during the follow-up phase. The investigators postulated that this was caused by the participant forgetting to take his anti-epileptic drug. The second participant experienced seizures throughout the intervention and control phases of the crossover study, even though his epilepsy had previously been well controlled; the patient's last seizure had been 7 years prior to the trial and adherence to both oxytocin and his anti-epileptic drugs were found to be excellent during the course of the trial. After the trial, the participant continued to suffer seizures two to three times every month. The same study had recruited a total of seven participants who had epilepsy and were stabilized on psychotropic drugs. None of them suffered seizure attacks during the course of the study, except for this aforementioned patient.
Female-specific adverse events
No female-specific adverse events were reported.
DISCUSSION
Based on the meta-analysis, the use of oxytocin in autistic patients is well tolerated, where the common side-effects reported do not differ significantly from placebo (all P-values > 0.1).
The cases of severe adverse events observed were likely not linked to oxytocin usage. The cases of hyperactivity and aggression reported by Yatawara et al. 82 were observed in both oxytocin and placebo groups, and occurred during week 1 of either phase 1 or phase 2 of the crossover trial. Interestingly, low plasma oxytocin has been linked with hyperactivity. 88 Therefore, it is unlikely that hyperactivity is linked to oxytocin usage. It is possible that the observed behavioral change was due to the participants being uncomfortable with using the nasal sprays, rather than due to the neurological effect of oxytocin. This is especially the case as patients with ASD are known to compulsively follow fixed routines, 1 and might perceive the initiation of the nasal sprays as a disruption to their previous routines.
It is not known if oxytocin played a role in the two cases of seizures that were observed by Munesue et al., 86 especially since other participants in that trial with epilepsy did not suffer similar adverse events despite receiving oxytocin as well. The seizure experienced by the first subject during the follow-up phase of the trial can be accounted for by the fact that the subject forgot to take his anti-epileptic drugs. The other case of seizure reported by the same trial is more perplexing, as the second subject, who had previously had well-controlled epilepsy, suddenly suffered multiple instances of seizures throughout the duration of the trial. A literature search found studies that suggest oxytocin could have both proconvulsive and anticonvulsive effects depending on the dosage. 89 Given the prevalence of epilepsy as a comorbidity in ASD, more research will have to be directed to assessing the safety of using oxytocin in patients who have epilepsy.
Some of the trials involved female participants and it was found that intranasal oxytocin did not trigger physiological responses related to the endogenous hormone, such as uterine contractions or galactorrhea. However, the low sample size of female participants, inclusion of prepubescent girls in studies, and the lack of gynecologists to monitor for these events are some limitations to accurate reporting of these female-specific adverse events.
Limitations of selected studies
The main limitation of the available studies in the literature is the small sample size. As seen from the forest plots provided, the statistical uncertainty of the results is high. It cannot be conclusively said that the results from this review are generalizable to the entire ASD population. The small sample size made the use of statistical heterogeneity unreliable. In addition, given the wide range of disorders associated with ASD, it would be more effective if the review performed subgroup analysis based on the different forms of ASD. However, due to the small sample size pool, the ability to perform subgroup analysis was limited.
The lack of female participants is also an issue. The sample size of females for this review was 24, which is too low to draw any conclusions about the safety of intranasal oxytocin in female participants. Given oxytocin's physiological functions in female subjects, more research needs to be done on the effects of applying this drug exogenously through the intranasal route.
Although attempts were made to contact authors of a study that did not report the adverse events fully, no response was received. Hence, the exclusion of Yatawara et al. 82 from the meta-analysis could potentially contribute to bias in the results.
This review also cannot determine how the dose of oxytocin could affect the safety of the drug in patients with ASD. The dose of oxytocin varied between studies, and due to the small sample size, subgroup analysis based on dosage would not be feasible.
Lastly, this review cannot determine the effect of intranasal oxytocin usage beyond a few months. Given the lack of a cure for ASD, if oxytocin is found effective in relieving the symptoms, it would potentially have to be used for a period of time beyond the study time frames in the clinical trials. The duration of the trials selected for this review ranged from 5 to 12 weeks.
Conclusion
Results from this systematic review support intranasal oxytocin as being well tolerated as a possible treatment in the ASD population. Therefore, largerscale clinical trials are recommended to assess the efficacy of intranasal oxytocin in the treatment of ASD. In addition, larger clinical trials would also help to further ascertain the adverse events of this drug reported in this review.
With larger sample sizes, it would be possible to conduct subgroup analysis to determine how various variables could affect the effects of intranasal oxytocin on patients with ASD. For instance, subgroup analysis could help determine how intranasal oxytocin affects patients of different sexes or ages. Testing of different dosage sizes could also help to determine the dose-response relation of intranasal oxytocin.
However, more emphasis on the monitoring of adverse events, especially in patients with epilepsy, is advised in future trials.
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